traccglobal.com

Why Do Medical Devices Need to Go Through Validation

Medical device validation is documented proof that a device, manufacturing process, or software consistently performs as intended under real conditions. It is legally required in the United States under FDA 21 CFR Part 820 / QMSR (effective February 2, 2026) and ISO 13485:2016 before any medical device can be sold to US patients. Skipping validation — or doing it incorrectly — leads to FDA warning letters, market bans, costly recalls, and potential criminal liability. From 2020–2024, the FDA oversaw nearly 4,000 medical device recalls in the US, with validation failures among the leading root causes.

What Is Medical Device Validation?

Medical device validation is the process of producing documented, objective evidence that a device, manufacturing process, or software system consistently does what it is supposed to do — in real-world or simulated real-world conditions. It answers one fundamental question: does this device actually work the way we say it does, every single time, for every patient?

The FDA defines validation as “establishing by objective evidence that the particular requirements for a specific intended use can consistently be fulfilled.” That word consistently is critical. A device that works 95% of the time may be acceptable in some industries. In healthcare, even a 1% failure rate can mean patient deaths.

Validation of medical devices is not a one-time checkbox. It covers design validation, manufacturing process validation, software validation, sterilization validation, packaging validation, and cleaning validation — often all required before a single unit ships to a US hospital, clinic, or patient.

Why Is Validation Legally Required in the USA?

If you are manufacturing or selling a medical device in the United States, validation is not optional. It is a legal mandate enforced by the FDA under multiple overlapping regulations.

The 2026 Milestone: FDA’s Quality Management System Regulation (QMSR)

On February 2, 2026, the FDA’s Quality Management System Regulation (QMSR) officially took effect — replacing the older Quality System Regulation (QSR) under 21 CFR Part 820. This is the single biggest update to US device manufacturing rules in decades. The QMSR formally incorporates ISO 13485:2016 by reference, meaning US device makers must now meet the same global quality management standard used in Europe, Canada, and Japan.

Critically, the QMSR strengthens validation requirements across design controls, process controls, and software systems. The FDA simultaneously retired its old QSIT inspection protocol, replacing it with a new inspection process aligned with the updated standard. If your medical device validation documentation was built for the old QSR, it almost certainly needs updating for 2026.

KEY US REGULATIONS REQUIRING MEDICAL DEVICE VALIDATION

21 CFR Part 820 / QMSR — Design controls, process validation, and software validation requirements for all US medical device manufacturers. Effective Feb 2, 2026.

ISO 13485:2016 — Now incorporated by reference in US law under the QMSR. Requires risk-based QMS with documented validation across all controlled processes.

ISO 14971 — Risk management requirements that directly inform what needs validation and at what rigor level.

FDA 510(k) / PMA Pathways — Both require V&V evidence in premarket submissions. Without completed validation, your submission will be rejected.

Why Regulators Don't Accept "Trust Us — It Works"

The reason regulators demand documented validation is simple: you cannot test every device that leaves a manufacturing line. A pacemaker manufacturer cannot implant a test pacemaker in every patient to verify it works. A surgical stapler cannot be fired inside every surgeon’s hand before it’s approved. Validation medical devices through controlled protocols is how manufacturers prove that their process is so reliable that every unit coming off that line can be trusted — without individually testing each one.

Process validation gives manufacturers and regulators statistical certainty. It says: “We have proven, with objective data collected across multiple production runs, that our process consistently produces devices that meet every specification.” That proof is the foundation of FDA’s pre-market clearance decisions.

Design Validation vs. Process Validation — What's the Difference?

These two types of medical device validation are often confused, but they answer completely different questions. Getting this distinction wrong in your FDA submission can cause immediate rejection.

AspectDesign ValidationProcess Validation
Core QuestionDoes this device meet user needs and intended use?Does our manufacturing process consistently make a conforming device?
FocusThe device itself — performance, safety, usabilityThe process — equipment, parameters, human factors in production
FDA Standard21 CFR 820.30 / QMSR Design Controls21 CFR 820.75 / QMSR Process Controls
When PerformedDuring or after design phase, before design freezeBefore production begins; repeated after any significant change
Typical ActivitiesSimulated use testing, clinical evaluation, human factors studiesIQ, OQ, PQ protocols; worst-case testing; statistical sampling
Required ForAll device types (Class I–III)Any process whose output cannot be fully verified by inspection

Both types of validation medical device work are required, and both must be completed and documented before FDA submission or market entry. Neither replaces the other.

IQ, OQ, PQ — The Three Stages of Process Validation Explained

IQ
Installation Qualification

Proves that equipment is installed correctly, meets manufacturer's specifications, and that all utilities and environmental conditions are in place as designed. "Is our equipment set up right?"

OQ
Operational Qualification

Demonstrates that the process operates within established limits to produce acceptable output. Tests worst-case operating conditions and defines the validated operating range. "Does our process work within spec?"

PQ
Performance Qualification

Proves that the process consistently performs under actual production conditions, using real materials, operators, and environment — typically run across multiple batches. "Can we do this reliably, every time?"

⚠ COMMON MISTAKE US MANUFACTURERS MAKE

Many small to mid-size device manufacturers start PQ before OQ is complete, or attempt to combine IQ and OQ to save time. The FDA considers this a validation protocol deviation — and it can invalidate your entire validation, forcing you to restart. Each phase must be formally approved before the next begins, with a documented protocol and report.

Which Medical Devices and Processes Need Validation?

Under FDA’s QMSR, validation is required for any process where the output cannot be fully verified by subsequent inspection or testing. In practice, this covers a wide range of manufacturing activities that are common across the medical device industry.

Processes that typically require medical device validation:

  • Sterilization processes (EtO, gamma, e-beam, steam) — arguably the most critical, as sterility cannot be retrospectively tested
  • Sterile packaging seal integrity and barrier validation
  • Injection molding and extrusion processes for plastic components
  • Welding (laser, ultrasonic, RF) and bonding processes
  • Automated assembly, dispensing, and robotic processes
  • Cleaning and decontamination processes for reusable devices
  • Labeling and coding systems where errors are not visually detectable
  • Software embedded in devices (firmware) and Software as a Medical Device (SaMD)
  • Lyophilization (freeze-drying) for diagnostic reagents
  • Liquid fill-and-finish processes for IVD assays

The key question is always: if this process produced a bad unit, would I know before it reached a patient? If the answer is “not reliably,” validation is mandatory.

Real Case Studies: What Happens When Validation Fails

The consequences of inadequate validation of medical devices are not theoretical. The following real-world cases illustrate exactly what the FDA finds during inspections — and the severe consequences that follow.

Case Study 1: The Ophthalmic Manufacturer Who Released Unsterilized Injection Kits
CASE STUDY

In 2025, an FDA warning letter revealed that a contract manufacturer of ophthalmic products had released 120 boxes of intravitreal injection kits as "sterile" — without ever sending them for sterilization. More alarmingly, the firm fabricated sterilization certificates to make it appear the products had been processed by an approved sterilizer.

The root cause: no validated process for sterilization traceability, no documented process controls, and a failed quality system that had no independent verification steps. The result was a Class I recall — the most serious category, indicating a reasonable probability that the product would cause serious injury or death.

Class I Recall Triggered FDA Warning Letter Issued Fraudulent Records Found
Case Study 2: AI Medical Devices Without Clinical Validation — A Johns Hopkins Study
CASE STUDY

A 2025 study published in JAMA Health Forum (Johns Hopkins University) analyzed 950 FDA-cleared AI-enabled medical devices. The findings were stark: devices with no clinical validation were significantly more likely to be recalled than those with retrospective or prospective clinical evidence.

Of the 60 devices associated with 182 recall events, the vast majority had not undergone clinical trials. The most common recall causes were diagnostic or measurement errors — the exact type of failure that proper validation is designed to prevent. Crucially, 43% of all recalls happened within just one year of FDA authorization.

60 devices → 182 recalls No validation = higher recall risk 43% recalled within 12 months
Case Study 3: The VR Medical Assessment Device — 3.5 Years of CAPA Delay
CASE STUDY

A US manufacturer of a VR-based medical assessment device opened a CAPA in 2021 to fix a software issue causing abnormal patient scores. The correction — a validation update — was still not implemented when the FDA inspected in 2025.

The FDA called this a systemic quality failure. The company faced potential consent decree, market restrictions, and import alerts due to prolonged delay in completing required validation.

3.5-year CAPA delay FDA Warning Letter Market restriction risk

AI-Enabled Medical Devices — Stricter Validation in 2025–2026

If your company is developing AI or machine learning-based medical devices, validation requirements in 2026 are more demanding than ever — and the stakes for getting it wrong are correspondingly higher.

The FDA’s August 2025 final guidance on Predetermined Change Control Plans (PCCPs) requires manufacturers to include, in their initial FDA submission, a formal plan describing how future AI algorithm changes will be developed, validated, and implemented. This means validation is no longer a one-time pre-market activity for AI devices — it must be embedded into the entire product lifecycle.

The Johns Hopkins study made clear what happens when this validation rigor is skipped: AI devices without clinical validation face a dramatically higher rate of real-world recalls. The FDA is responding by moving toward a lifecycle-based regulatory model for AI, where post-market performance monitoring is treated as a continuous validation activity, not just a reporting obligation.

✓ WHAT 2026 MEANS FOR YOUR AI DEVICE VALIDATION PLAN

Your FDA premarket submission must now include a PCCP documenting how algorithm updates will be validated. Post-market surveillance must include real-world performance monitoring with defined thresholds that trigger revalidation. Software validation under IEC 62304 and risk management under ISO 14971 must be integrated from day one of development — not added at the end.

When Should Validation Begin in the Product Development Process?

This is one of the most consequential decisions a medical device manufacturer makes — and one of the most commonly made incorrectly. Many US startups treat validation as the last step before they submit to the FDA. This is the wrong approach, and it costs companies millions of dollars and months of delay every year.

Validation planning must begin at design inputs, not design freeze. The reason is simple: your design choices directly determine what validation is needed and what evidence is possible. If you build a device using a sterilization method that is difficult to validate (for example, choosing a material incompatible with your target sterilization modality), you will discover this problem during validation — at the most expensive possible moment.

The correct timeline for validation medical devices:

  • Concept/Feasibility Phase: Identify which processes will require validation; begin validation planning
  • Design Development Phase: Select materials, processes, and equipment with validation feasibility in mind
  • Design Verification Phase: Complete design verification; draft validation protocols (IQ/OQ/PQ) for manufacturing processes
  • Design Validation Phase: Execute design validation in simulated or actual use conditions
  • Process Validation Phase: Run IQ → OQ → PQ with final production equipment, materials, and personnel
  • FDA Submission: Include complete validation documentation in your 510(k) or PMA

Starting validation early doesn’t just reduce risk — it actively compresses your time to market. According to industry data, manufacturers who integrate validation planning into early design phases complete validation 30–40% faster than those who treat it as a late-stage activity.

Medical Device Validation Checklist for US Manufacturers (2026)

Use this checklist to assess whether your medical device validation program meets current FDA QMSR and ISO 13485:2016 requirements:

  • Validation Master Plan (VMP) is documented and approved, covering all processes requiring validation
  • Design inputs are formally defined, and design validation confirms user needs are met in actual or simulated use
  • All manufacturing processes whose output cannot be fully verified by inspection have written IQ, OQ, and PQ protocols
  • Validation protocols are approved before execution — not retroactively written after results are known
  • Equipment and software used in validation are calibrated and qualified
  • Statistical sampling plans are scientifically justified (not arbitrary)
  • Worst-case conditions are formally identified and tested during OQ
  • PQ runs are completed using actual production materials, operators, and environmental conditions
  • Validation reports document actual results vs. acceptance criteria — not just “pass/fail” summaries
  • Any changes to validated processes trigger a formal revalidation assessment
  • Software validation is performed for all software impacting device safety or quality (per IEC 62304)
  • Sterilization validation is performed and documented per ISO 11135, 11137, or applicable standard
  • Packaging validation covers seal integrity, sterile barrier, and distribution simulation
  • All validation documentation is controlled, version-managed, and retrievable for FDA inspection
  • Post-market surveillance includes process monitoring that would trigger revalidation if performance drifts

How TraccGlobal Helps US Medical Device Manufacturers With Validation

At TraccGlobal, medical device validation is one of our core specializations. We work with manufacturers, startups, and global companies entering the US market who need validation documentation that is complete, defensible, and aligned with the 2026 QMSR and ISO 13485:2016 requirements.

Our validation services cover end-to-end support — from Validation Master Plan development through IQ, OQ, and PQ protocol writing, execution oversight, and final report preparation. For companies seeking FDA 510(k) clearance or PMA approval, we build validation packages that are designed from the ground up to withstand FDA review and inspection.

We also work with companies who have received FDA 483 observations or warning letters related to validation deficiencies — helping them remediate their programs, close open CAPAs, and restore compliance before enforcement escalates.

TraccGlobal serves clients across the US and globally, with deep expertise in FDA regulatory strategy, ISO 13485 QMS implementation, and medical device process validation documentation. Our team has a 98% first-attempt approval rate — because we build validation programs that are right the first time.

Frequently Asked Questions About Medical Device Registration in Saudi Arabia

What is medical device validation, and is it the same as verification?
No — they are distinct but related activities. Verification confirms that a device meets its design specifications (did we build it right?). Validation confirms that the device meets user needs and intended use in real-world conditions (did we build the right thing?). Both are required under FDA QMSR and ISO 13485. You must verify before you validate.
Yes, without exception. The FDA’s QMSR (effective February 2, 2026) mandates validation as part of design controls and process controls for all medical device manufacturers. Selling a device in the US without completed, documented validation exposes your company to warning letters, import alerts, injunctions, consent decrees, and potential criminal prosecution of company officers.
IQ (Installation Qualification) verifies that equipment is installed correctly per manufacturer specifications. OQ (Operational Qualification) demonstrates that the process operates within acceptable limits under worst-case conditions. PQ (Performance Qualification) proves the process consistently performs under real production conditions across multiple runs. All three phases are required in sequence, each with a formal protocol and report.
For a typical Class II 510(k) device, the full validation cycle — from protocol drafting through final reports — generally takes 6 to 18 months depending on device complexity, the number of processes requiring validation, and whether any failures require investigation and rerunning. Validation started early in design can compress this timeline substantially.
Yes. Any software that is part of a medical device (embedded firmware) or that functions as a medical device (SaMD) requires software validation per FDA guidelines and IEC 62304. The rigor required depends on the software safety class. For AI/ML-based SaMD, the FDA’s 2025 PCCP guidance adds additional requirements for lifecycle validation management.
Any change to a validated process — new equipment, new supplier, new facility, parameter changes, new software — requires a formal change control assessment. Depending on the change’s impact, you may need partial revalidation (e.g., new OQ only) or complete revalidation from IQ through PQ. Failure to revalidate after a significant change is one of the most common FDA inspection findings.
Yes, and for many small manufacturers this is the most efficient path. A qualified regulatory consultant like TraccGlobal can develop your Validation Master Plan, write IQ/OQ/PQ protocols, execute validation studies, prepare final reports, and ensure all documentation meets FDA and ISO 13485 requirements. However, the manufacturer retains legal responsibility — the consultant acts on your behalf, not in place of you.
The Quality Management System Regulation (QMSR), effective February 2, 2026, replaces the old 21 CFR Part 820 and incorporates ISO 13485:2016 by reference into US law. For validation specifically, this means all validation activities must now be aligned with both FDA requirements and ISO 13485 — which has slightly different emphasis and documentation requirements than the old QSR. Companies that were compliant with the old QSR should perform a gap assessment against ISO 13485:2016 to identify any validation program updates needed.

Ready to Start Your Validation Program?

Whether you're validating your first device, preparing for an FDA inspection, or fixing a failed validation — TraccGlobal is your expert partner. Get a free consultation with our regulatory specialists today.

View Our Validation Services

TraccGlobal · Gurugram, India · Serving US & Global Medical Device Manufacturers · traccglobal.com

Facebook
Twitter
Pinterest
LinkedIn
Picture of Rajesh

Rajesh

Auther & Publisher

All Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest Post